Disease Trends in the Oligonucleotide Space
Using data derived from Beacon as of April 2025, the slides cover the following:
- Disease trend insights across over 2,100 therapies, with deep dives into the rise of siRNA and ASO modalities.
- Pipeline growth snapshots, including 60+ new siRNA programs since January 2025 and a surge in early-stage oligonucleotide assets.
- Clinical progress tracking, revealing trial activity by disease type and phase, and showcasing cardiovascular drugs with standout efficacy data.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
